{"filing":{"accession_number":"0001140361-26-031506","cik":"0001855129","ticker":"GHRS","company_name":"GH Research PLC","form":"6-K","filing_date":"2026-08-06","report_date":"2026-06-30","primary_document":"ef20075260_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1855129/000114036126031506/ef20075260_6k.htm"},"events":[{"id":25453,"run_id":23105,"accession_number":"0001140361-26-031506","anchor_item_number":"EX-99.3","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"GH Research reported second quarter 2026 financial results, including a net loss of $15.1 million, cash position of $362.7 million, and detailed R\u0026D and G\u0026A expenses, along with condensed consolidated interim financial statements.","company_name":"GH Research PLC","ticker":"GHRS","filing_date":"2026-08-06","form":"6-K","submitted_at":null,"items":[{"id":26288,"accession_number":"0001140361-26-031506","item_number":"EX-99.3","item_title":"ef20075260_ex99-3.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This exhibit is a press release announcing GH Research's second quarter 2026 financial results, including condensed consolidated interim financial statements (statement of comprehensive loss and balance sheet), cash position of $362.7 million, R\u0026D and G\u0026A expenses, and net loss of $15.1 million. The document explicitly states \"GH Research Reports Second Quarter 2026 Financial Results\" and provides detailed quarterly financial metrics and comparisons to prior year, which is the hallmark of an earnings release.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:46:18.464402+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":25454,"run_id":23105,"accession_number":"0001140361-26-031506","anchor_item_number":"EX-99.4","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"GH Research announced positive Phase 2b clinical trial results for GH001 (mebufotenin) in treatment-resistant depression, demonstrating primary efficacy endpoints (MADRS reduction of -15.5 vs placebo, P\u003c0.0001) and remission rates of 57.5% at Day 8 and 73% at 6 months in open-label extension completers, with Phase 3 initiation planned for 2026.","company_name":"GH Research PLC","ticker":"GHRS","filing_date":"2026-08-06","form":"6-K","submitted_at":null,"items":[{"id":26289,"accession_number":"0001140361-26-031506","item_number":"EX-99.4","item_title":"ef20075260_ex99-4.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"This exhibit is a corporate presentation dated August 2026 disclosing Phase 2b clinical trial results for GH001 (mebufotenin) in treatment-resistant depression, including primary efficacy endpoints (MADRS reduction of -15.5 vs placebo, P\u003c0.0001), remission rates (57.5% at Day 8, 73% at 6 months in OLE completers), safety data, and pipeline status. While formatted as a presentation rather than a traditional earnings release, it discloses material clinical and operational milestones (Phase 3 initiation in 2026, cash position of $362.7m as of June 30, 2026) that would affect investor assessment of the company's progress and value. The disclosure of positive Phase 2b results and advancement toward Phase 3 is a material event for a clinical-stage biotech company.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:46:18.464402+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26286,"accession_number":"0001140361-26-031506","item_number":"EX-99.1","item_title":"ef20075260_ex99-1.htm","event_type":"periodic_interim","event_domain":"periodic","is_material":false,"confidence":0.95,"reasoning":"This exhibit is an unaudited condensed consolidated interim financial statement for the six months ended June 30, 2026, prepared in accordance with IAS 34 \"Interim Financial Reporting.\" It presents comprehensive loss, financial position, changes in equity, and cash flows for a clinical-stage biopharmaceutical company. This is a periodic interim financial report itself, not a discrete event or earnings release announcement, and should be deferred for separate processing as a periodic_interim filing.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:46:18.464402+00:00","company_name":"GH Research PLC","ticker":"GHRS","filing_date":"2026-08-06"},{"id":26287,"accession_number":"0001140361-26-031506","item_number":"EX-99.2","item_title":"ef20075260_ex99-2.htm","event_type":"periodic_interim","event_domain":"periodic","is_material":false,"confidence":0.95,"reasoning":"This exhibit is a Management's Discussion and Analysis (MD\u0026A) accompanying unaudited condensed consolidated interim financial statements for the three and six months ended June 30, 2026, prepared under IAS 34. The document explicitly states it is designed to provide \"narrative explanation of our financial condition and results of operations\" in conjunction with interim financial statements. This is a periodic interim financial report, not a discrete event or earnings release press announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:46:18.464402+00:00","company_name":"GH Research PLC","ticker":"GHRS","filing_date":"2026-08-06"},{"id":26288,"accession_number":"0001140361-26-031506","item_number":"EX-99.3","item_title":"ef20075260_ex99-3.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This exhibit is a press release announcing GH Research's second quarter 2026 financial results, including condensed consolidated interim financial statements (statement of comprehensive loss and balance sheet), cash position of $362.7 million, R\u0026D and G\u0026A expenses, and net loss of $15.1 million. The document explicitly states \"GH Research Reports Second Quarter 2026 Financial Results\" and provides detailed quarterly financial metrics and comparisons to prior year, which is the hallmark of an earnings release.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:46:18.464402+00:00","company_name":"GH Research PLC","ticker":"GHRS","filing_date":"2026-08-06"},{"id":26289,"accession_number":"0001140361-26-031506","item_number":"EX-99.4","item_title":"ef20075260_ex99-4.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"This exhibit is a corporate presentation dated August 2026 disclosing Phase 2b clinical trial results for GH001 (mebufotenin) in treatment-resistant depression, including primary efficacy endpoints (MADRS reduction of -15.5 vs placebo, P\u003c0.0001), remission rates (57.5% at Day 8, 73% at 6 months in OLE completers), safety data, and pipeline status. While formatted as a presentation rather than a traditional earnings release, it discloses material clinical and operational milestones (Phase 3 initiation in 2026, cash position of $362.7m as of June 30, 2026) that would affect investor assessment of the company's progress and value. The disclosure of positive Phase 2b results and advancement toward Phase 3 is a material event for a clinical-stage biotech company.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:46:18.464402+00:00","company_name":"GH Research PLC","ticker":"GHRS","filing_date":"2026-08-06"}]}